Celltrion

Main menu

Corporate History

Pathway of Celltrion towards Progress and Innovation

2018

December
Application for approval of
RemsimaSC is submitted in the EMA
Herzuma is approved by US (FDA)
November
Truxima is approved by US (FDA)
August
Begins clinical trial phase 3 of CT-P16
Begins clinical trial phase 1ㆍ3 of CT-P17
June
Launches Bio CDMO business
Feburary
Herzuma is approved by Europe (EMA)
Lists on KOSPI

2017

September
Decision to transfer to KOSPI
July
Begins clinical trial phase 1 of CT-P16
Feburary
Truxima is approved by Europe (EMA)

2016

December
Begins clinical trial phase 2b of CT-P27
November
Remsima begins sales in US
Truxima is approved by Korea (MFDS)
June
Begins global clinical trial phase 1 and 3 of CT-P13 SC (Remsima SC)
May
Decision to expand Plant 1(50,000L) and build Plant 3
April
Remsima is approved by US (FDA)

2015

June
Plant 1 and Plant 2 receive approval from the FDA of U.S. on all cGMP manufacturing facilities
February
Remsima begins sales in Europe (Total of 12 countries including Germany, France, UK, Italy)

2014

February
Begins clinical trial phase 2a of CT-P27
January
Herzuma is approved by Korea (MFDS) and Canada (Health Canada)

2013

November
Completes clinical trial phase 1 of CT-P27
August
Remsima is approved by Europe (EMA)
April
Begins global clinical trial of CT-P27

2012

July
Remsima is approved by Korea (MFDS)

2011

December
Completes clinical trial of Herzuma
November
Begins global clinical trial of Truxima
Completes clinical trial of Remsima
October
Mechanical completion of Plant 2(90,000L)

2010

May
Attracted large-scale foreign investment (Singapore Temasek Holdings, 208 billion KRW)
March
Begins global clinical trial of Remsima

2009

October
Completes building the worldwide biosimilar sales network
September
Contract of cooperation development on new drugs for comprehensive influenza treatment antibodies with the US Center for Disease Control (CDC)
August
Begins global clinical trials of Herzuma

2008

August
Initial Public Offering(IPO)

2007

December
Plant 1 receives cGMP facility approval by the US FDA

2005

July
Mechanical completion of Plant 1(50,000L)
June
Supply agreement with BMS(Bristol-Myers Squibb)

2002

February
Foundation of CELLTRION
위로 가기